Archives of oto-rhino-laryngology

, Volume 228, Issue 2, pp 127–134 | Cite as

Use of phytohemagglutinin in the treatment of maxillary cancer

  • M. Okuda
  • K. Sakaguchi
  • S. Tomiyama
  • M. Takahashi


Twenty-four patients with maxillary squamous cell carcinoma were treated with 50 μg of phytohemagglutinin (PHA), saturated into pieces of gelatin sponge, and applied to the maxillary sinus which was in advance surgically exposed via the peroral route. Treatment was combined with cobalt 60 irradiation at 4,000 rads (200 rads×20 doses over a one month period) and concurrent arterial infusion of 5-fluorouracil (5-FU) with a total dosage of 5,000 mg (250 mg× 20 doses). After 20 treatments with phytohemagglutinin, gross examination showed that tumors were no longer apparent in 83.3% of the cases treated with PHA vs. 52.6% in the control group without PHA. On histological examination, 66.6% in the PHA group showed no signs of tumors vs. 15.8% in the control group. Microscopically, the disappearance of the tumors was frequently observed in tumor of T2 more than that of T3 in extent of primary tumor. No side effects were observed nor was there a significant difference between the control group and the PHA group in the 3-year crude survival rate (control group: 68.4%; PHA group: 62.5%)

Key words

Phytohemagglutinin (PHA) Local treatment of cancer Maxillary squamous cell carcinoma 

Phytohaemagglutinin zur Behandlung von Oberkieferkarzinomen


Behandlung von 24 Patienten mit einem Plattenepithelkarzinom der Kieferhöhle mit 50 μg Phytohaemagglutinin (PHA). Das Präparat wurde mittels Gelita in die peroral eröffnete Kieferhöhle eingebracht und die Therapie mit einer Telekobaltbestrahlung von 4000 rad (20×200 rad über einen Monat) sowie arteriellen Infusionen von 5-Fluorouracil (5-FU), 20×250 mg, kombiniert. Nach 20 Behandlungen mit PHA war der Tumor in 83,3% der Fälle verschwunden, während er bei den Patienten ohne PHA-Therapie nur in 62,6% nicht mehr nachzuweisen war. Bei der histologischen Untersuchung fand sich in der PHA-Gruppe in 66,6% kein Tumor mehr, bei der Gruppe ohne PHA dagegen nur in 15,8%. Nebenwirkungen wurden nicht beobachtet. In der 3 Jahre-Überlebensrate bestand zwischen beiden Gruppen kein signifikanter Unterschied.


Phytohaemagglutinin lokale Krebsbehandlung Plattenepithelkarzinom der Kieferhöhle 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonforte RF, Topilsky MM, Siltzbach LE, Glade PR (1972) Phytohemagglutinin skin test. J Pediatr 81:775–780Google Scholar
  2. Blaese RM, Weiden PM, Oppenheim JJ, Waldamann TA (1973) Phytohemagglutinin as a skin test for the evaluation of cellular immune competence in man. J Lab Clin Med 81:538–548Google Scholar
  3. Brugarolas A, Takita H, Moore GE (1972) Effect of syngeneic tumor cells bound to Concanavalin A on tumor growth. J Surg Oncol 4:123–130Google Scholar
  4. David JR (1971) Migration inhibitory factor and mediators of cellular hypersensitivity in vitro. In: Amos B (ed) Progress in immunology. Academic Press, New York LondonGoogle Scholar
  5. Epstein LB, Smith ChW (1968) The in vivo induction of mouse lymphocyte tranformation by phytohemagglutinin. J Immunol 100:421–435Google Scholar
  6. Hayes DM, Spurr ChL (1966) Use of phytohemagglutinin to stimulate hematopoiesis in humans. Blood 27:78–84Google Scholar
  7. Humble JG (1963) In vivo action of phytohemagglutinin in severe human aplastic anemia. Nature 198:1313–1314Google Scholar
  8. Inbar M, Ben-Bassat H, Sachs L (1972) Inhibition of ascites tumor development by Concanavalin A. Int J Cancer 9:143–149Google Scholar
  9. Iwamoto H (1971) Head and neck tumor. T Kitamura Igakushoin, Tokyo (in Japanese)Google Scholar
  10. Konno S, Togawa K, Azuma G, Uchikoshi S, Tooyama T (1975) Histological type and staging of the maxillary carcinoma as related to histopathological effect of combined therapy. Jpn J Otol 78:1170–1176 (in Japanese)Google Scholar
  11. Lozzio BB, Machado EA, Chernoff AI (1969) Functional and cellular alterations produced by phytohemagglutinin. Acta Haematol 41:349–358Google Scholar
  12. Machado E, Lozzio BB (1968) Structural alterations after in vivo administration of phytohemagglutinin. Nature 218:268–269Google Scholar
  13. Matsumura Y, Kurita Y, Takayama K, Akazaki I, Hiroto I, Takei O, Nandate M, Yamada A (1974) Standardization of treatment of cancer of the maxillary sinus related to histological type. Otologia (Fukuoka) 20:371–377 (in Japanese)Google Scholar
  14. Norins LC, Marshall WH (1964) Letters to the editor. Lancet II:648Google Scholar
  15. Okuda M, Sakaguchi L, Tomiyama S, Takahashi M (1977) Local treatment of cancer with phytohemagglutin. Cancer Chemother 4:389–393 (in Japanese)Google Scholar
  16. Robinson E (1967) The effect of phytohemagglutinin on the leucocyte count in rats. Vox Sang 13:467–471 (1967)Google Scholar
  17. Shimozato Y (1969) Histopathological changes of cancer by irradiation. Ganno-Rinsho 15:261–265 (in Japanese)Google Scholar
  18. Shoham J, Inbar M, Sachs L (1970) Differential toxicity on normal and transformed cells in vitro and inhibition of tumor development in vivo by Concanavalin A. Nature 227:1244–1246Google Scholar
  19. Wahi PN (1971) Histological typing of oral and oropharyngeal tumors. WHO Monograph Series (Geneva)Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • M. Okuda
    • 1
  • K. Sakaguchi
    • 1
  • S. Tomiyama
    • 1
  • M. Takahashi
    • 2
  1. 1.Dept. OtolaryngologyNippon Medical SchoolTokyoJapan
  2. 2.Dept. OtolaryngologyAsahikawa Medical CollegeAsahikawaJapan

Personalised recommendations